The outbreak of COVID-19 caught the world off guard and severely constrained people's ability to live their lives to the fullest. Responses have been non-personal and broad (such as social distancing) or focused medical approaches targeting specific strains (such as vaccines). And while these solutions are crucial and these vaccines were developed at unprecedented speed, all responses are reactive.
What the world needs is a proactive approach. Nature harbors millions of unknown viruses and with virus mutations in humans, new infections are a given. However, we don’t know which one will strike next. The current reactive approach does not prepare us for these future threats.
It’s time for a new approach.
our new Approach
To protect from what comes next, we need to act proactively and be ready for a broad range of viruses. At Leyden Labs, we expand the armamentarium of available tools by developing our platform and products with three innovative concepts:
The millions of unknown viruses harbored in nature can be grouped in a few dozen of viral families. By targeting the commonalities of these families, we can develop protection against entire virus families at once, including the unknown variants. Our focus is on respiratory viruses like influenza and coronaviruses, which are most likely to cause pandemics because they are transmitted through the air.
Through our platform, we are developing nasal sprays that provide immediate protection because they attack viruses where they attack us – in our nasal passages – keeping people safe from catching infections and preventing people from spreading them to others.
Through our nasal sprays we deliver antibodies in the mucosa of the nasal passages that provide the user instant protection. It does not rely on the defense of a person’s own immune system and can therefore also effectively support population groups at risk, such as elderly and immunocompromised people.
We are working toward accessible, self-administrable products, so people can take control and live their lives to the fullest by protecting themselves against catching infections and preventing transmission to others. In January 2022, we announced that we have an exclusive license to develop and commercialize CR9114, a pan-influenza antibody protecting against influenza A and B. We are working hard to develop our PanFlu product candidate and advance it into the clinic.
The city of Leiden (The Netherlands) inspired our name. For centuries, Leiden is known for unconventional thinking, the freedom to express this openly and scientific breakthroughs such as the first publications of Galileo’s famous Discorsi.
Our team of energetic, experienced and curious people is ready to go beyond to accomplish our mission. We strive for a fantastic life for all people. We aim for the highest, think unconventionally and focus relentlessly on delivering the impossible. In our team trust, integrity and inclusiveness are a given.
Meet our fantastic team. Together, we work towards our mission of freeing you from viruses.
Preclinical & CMC
Clinical & Epidemiology
Mucosal Platform Discovery
Lotte van Alst
Finance & Control
Preclinical & CMC
Our Supervisory Board
Founder and Chair of the Supervisory Board
John Martin (In memoriam)
Former CEO Gilead Sciences
Onno van de Stolpe
Former CEO Galapagos.
Former CMO GSK and Global Head of Development at Novartis
Professor in Pediatrics and Microbiology, Medicine and Neurosurgery at University of Alabama
Pharm.D., Chief Executive Officer of Xilio Therapeutics
General Partner GV
President and Managing Partner F-Prime Capital
Chief Investment Officer and Founder Casdin Capital
join our mission
At Leyden Labs, we want to free humanity from the burden of respiratory viruses to let people live life to the fullest. We are moving fast and growing quickly. Are you interested in contributing?
We work closely together with academics, commercial researchers and other commercial parties to further develop our business.
We aim to prepare society for future pandemics and are keen to help governments and institutions do so.
We are open to discussions with interested investors.
We are growing quickly and always looking for the best people to work with.
Leyden Laboratories B.V.
2333 BD Leiden
Leyden Laboratories Co.
191 Dexter Avenue
Leyden Labs S.L.
Avda. del Conocimiento 41.A210
Centro de Empresas
Parque Tecnológico de la Salud